BioAge Labs, Inc.
BIOA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001709941
In the last 90 days, BioAge Labs, Inc. insiders filed 0 open-market purchases and 1 sale; 150 institutions reported holding it in 13F filings for Q2 2026, worth $924.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BioAge Labs, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $1.58M in total
- Insiders trading
- 1
- Net value
- −$1.58M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BioAge Labs, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Barton Shane | Principal Accounting Officer | 0 | Jul 1, 2026 | 2 |
| Garnier Jean Pierre | Director | – | Jun 12, 2026 | 1 |
| Healy James | Director | 26,497Indirect | Jun 12, 2026 | 1 |
| Enright Patrick G | Director | 1,710,589Indirect | Jun 12, 2026 | 1 |
| Davidson Michael H. | Director | – | Jun 12, 2026 | 1 |
| Hemrajani Rekha | Director | 3,000 | Jun 12, 2026 | 1 |
| Pande Vijay Satyanand | Director | 1,119,195Indirect | Jun 12, 2026 | 1 |
| Goldstein Dov A MD | Chief Financial Officer | 36,575 | Apr 24, 2026 | 6 |
| Rubin Paul D | Chief Medical Officer | 0 | Apr 3, 2026 | 7 |
| Fortney Kristen | Chief Executive Officer | 976,949 | Feb 19, 2026 | 2 |
| Morgen Eric | Chief Operating Officer | – | Feb 19, 2026 | 1 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 1,629,529Indirect | Oct 1, 2024 | 0 |
| Chen Bihua | Other: Former 10% Owner | 1,629,529Indirect | Oct 1, 2024 | 0 |
| Cormorant Private Healthcare Fund IV LP | Other: Former 10% Owner | 1,629,529Indirect | Oct 1, 2024 | 0 |
| Cormorant Private Healthcare Fund V LP | Other: Former 10% Owner | 1,629,529Indirect | Oct 1, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)4:27 PM ET | Jun 29-30 | 2 days | Barton ShanePrincipal Accounting Officer | SSale | −62.6K | $25.20 | −$1.58M | −100.0%0 after | 2 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Rubin Paul DChief Medical Officer | SSale | −8.82K | $17.81 | −$157.1K | −100.0%0 after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Rubin Paul DChief Medical Officer | SSale | −7.43K | $20.30 | −$150.9K | −100.0%0 after | 10b5-1 |
| Feb 3, 2026 (view filing) | Feb 2 | 1 day | Rubin Paul DChief Medical Officer | SSale | −7.43K | $18.75 | −$139.4K | −100.0%0 after | 10b5-1 |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Fortney KristenChief Executive Officer | SSale | −233.1K | $18.12 | −$4.22M | −19.3%976.9K after | 10b5-1 |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Goldstein Dov A MDChief Financial Officer | SSale | −27.0K | $19.70 | −$531.8K | −54.6%22.4K after | 4 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Rubin Paul DChief Medical Officer | SSale | −7.43K | $12.85 | −$95.5K | −100.0%0 after | 10b5-1 |
| Dec 11, 2025 (view filing) | Dec 9 | 2 days | Rubin Paul DChief Medical Officer | SSale | −18.0K | $12.00 | −$216.0K | −100.0%0 after | 10b5-1 |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Rubin Paul DChief Medical Officer | SSale | −68.9K | $10.19 | −$702.1K | −100.0%0 after | 10b5-1 |
| Mar 10, 2025 (view filing) | Sep 27, 2024 | 164 days | Hemrajani RekhaDirector | PPurchase | +3.00K | $18.00 | +$54.0K | New position3.00K after | Amended |
| Mar 10, 2025 (view filing) | Sep 27, 2024 | 164 daysLate | Barton ShanePrincipal Accounting Officer | PPurchase | +2.63K | $18.00 | +$47.4K | New position2.63K after | |
| Oct 3, 2024 (view filing) | Oct 1-3 | 2 days | Pande Vijay SatyanandDirector | PPurchase | +219.2K | $19.75 | +$4.33M | +24.4%1.12M after | 3 lots |
| Oct 1, 2024 (view filing)4:01 PM ET | Sep 27 | 4 days | Cormorant Asset Management, LP and 3 othersOther: Former 10% Owner | PPurchase | +450.0K | $18.00 | +$8.10M | +38.2%1.63M after | |
| Sep 27, 2024 (view filing) | Sep 27 | Same day | Pande Vijay SatyanandDirector | PPurchase | +900.0K | $18.00 | +$16.2M | New position900.0K after | |
| Sep 27, 2024 (view filing) | Sep 27 | Same day | Enright Patrick GDirector | PPurchase | +400.0K | $18.00 | +$7.20M | +30.5%1.71M after | |
| Sep 27, 2024 (view filing) | Sep 27 | Same day | Healy JamesDirector | PPurchase | +666.7K | $18.00 | +$12.0M | New position26.5K after | 5 lots |